slide1 l.
Download
Skip this Video
Download Presentation
nanomedinc

Loading in 2 Seconds...

play fullscreen
1 / 18

nanomedinc - PowerPoint PPT Presentation


  • 171 Views
  • Uploaded on

Carbon Nanotube-Based Cancer Therapeutics. Medical Nanotechnologies Incorporated. Rob Burgess, Ph.D. Founder and President. www.nanomedinc.com. Zyvex Corporation and Zyvex Performance Materials – Carbon Nanotube Functionalization. Zyvex Performance Materials’ Technical Approach.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'nanomedinc' - shina


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Carbon Nanotube-Based Cancer Therapeutics

Medical Nanotechnologies Incorporated

Rob Burgess, Ph.D.Founder and President

www.nanomedinc.com

zyvex performance materials technical approach
Zyvex Performance Materials’ Technical Approach

Two distinct functions:

  • Non-damaging binding to the CNT
  • Customizable adhesion to host material (example: polymer such as epoxy)

Zyvex NanoSolve® Enhanced Composites

  • Sizing agent or tailored coupling agent
  • Exfoliation of CNT
  • Uniform dispersion
  • Adhesion to polymer
  • Not a surfactant
  • Other advanced capabilities
    • Process knowledge
    • Custom formulations

Kentera™ Technology Enables CNTs in Composites

kentera conjugated carbon nanotubes are soluble in water
Kentera-Conjugated Carbon Nanotubes are Soluble in Water
  • Customizable side chains confer solubility
rf mediated cnt thermal conductivity
RF-mediated CNT Thermal Conductivity

RF field

RF

Transmitter

RF

Receiver

Target

area

CNT-introduced

regions

Source: Adapted from US Patent Application 2005/0251234 A1

Inventors: Kanzius et al.

Source: Gannon et al.

cnt functionalization
CNT Functionalization

Carbon nanotubes can be functionalized with antibodies and polar lipids.

AFM

TEM

AFM

Source: Chakravarty et al.

Source: Marches et al.

intracellular accumulation of pedot pss conjugated carbon nanotubes

CNT Intracellular Delivery

Intracellular Accumulation of PEDOT/PSS-Conjugated Carbon Nanotubes

HEK293 Cells

72 hours post-treatment

Source: Draper et al.

carbon nanotube properties make them a unique platform for therapeutic applications
Carbon nanotube properties make them a unique platform for therapeutic applications.
  • Organized Structure
  • Mechanism of Action Known
  • RF and Near IR Sensitive
  • Electrically and Thermally Conductive
  • Can be Functionalized with a Variety of Molecules
  • Can Penetrate Cells
antibody cnt cell surface binding and cytotoxicity
Antibody/CNT Cell Surface Binding and Cytotoxicity

Antibody/lipid-coated carbon nanotubes are noncytotoxic and bind specifically to cancer cells.

Daudi Cells

Source: Chakravarty et al.

Source: Marches et al.

cell surface binding
Cell Surface Binding

Antibody-coated carbon nanotubes bind specifically to cancer cells.

Source: Chakravarty et al.

cnt based cancer therapeutics
CNT- Based Cancer Therapeutics

Cancer cells are effectively ablated by carbon nanotubes in the presence of NIR light.

Source: Chakravarty et al.

slide13

CNT- Based Cancer Therapeutics

Panc-1 cells containing Kentera-conjugated carbon nanotubes are efficiently ablated upon RF exposure.

No SWNTs

11% PI Stained

SWNTs

99.7% PI Stained

Source: Gannon et al.

slide14

Intratumoral CNT/Kentera injections demonstrate RF-mediated cellular ablation.

Kentera/SWNTs

Kentera

H&E

TUNEL

Source: Gannon et al.

criteria for success targeted cnt cancer therapeutics
Criteria for Success: Targeted CNT Cancer Therapeutics
  • Functionality
    • Dispersion - Effective aqueous dispersion must be demonstrated.
    • Efficacy – CNT’s must aggressively ablate targeted tissue.
  • Toxicity – CNT’s and polymer functionalization must be demonstrated as nontoxic.
  • Specificity – CNT’s must be successfully targeted to tumorigenic tissue and away from healthy tissue.
slide17

Acknowledgments

Zyvex Corporation

Jim Von Ehr

Gareth Hughes, Ph.D.

Tanja Kmecko

UT-Dallas

Rocky Draper, Ph.D.

Paul Pantano, Ph.D.

Inga Musselman, Ph.D.

UT-SW Medical Center

Ellen Vitetta, Ph.D.

Radu Marches, Ph.D.

Pavitra Chakravarty, Ph.D.

UT-MD Anderson Cancer Center

Steve Curley, M.D.

Nanoco, LLC

Peter Wilk, M.D.

slide18

For Further Information

Rob Burgess, Ph.D.

President

Medical Nanotechnologies, Inc.

Email: rob.burgess@nanomedinc.com

Phone: 214-440-2311

www.nanomedinc.com